Genetics and Pathology
Dag Hammarskjöldsv. 20, 751 85, Uppsala, Sweden
Education and degrees
1984 PhD Biochemical characterization of MHC,transplantation antigens. Dept. of Cell Research, Uppsala University Supervisor Per Peterson.
1979 Medical School,Uppsala University, semester 1-8
Current and previous positions
1997- Professor in Medical Biochemistry, Uppsala University
1986-1996 Postdoc and Assistant member, Ludwig Institute for Cancer Research (Uppsala Branch)
1984-1986 Postdoc, Dept. of Virology, University of Chicago, USA
1981-1984 PhD student, Dept. of Cell Research, Uppsala University
Distinctions and awards
2009, 2016 Award “Wallenberg Scholar” by the Knut and Alice Wallenberg foundation
2003 Elected member of the Royal Swedish Science Academy
Supervision of doctoral students
Have served as main supervisor for 21 PhD students.
Molecular mechanisms in angiogenesis, vascular leakage, angiogenic growth factor signal transduction, VEGF, VEGFRs, heparan sulfate, neuropilins, cancer tumor vascularization, immune regulation, histidine-rich glycoprotein (HRG).
Publications on PubMed: 250 as Claesson-Welsh L and Claesson L (PubMed)
No. of citations: 27,829
Hirsch index: 85 (Scopus)
Patent applications: 4 granted patents
My research focus is on molecular regulation of endothelial cell biology, in particular with regard to VEGF-induced leakage of molecules and cells in cancer and eye diseases. I have seen the European vascular biology field evolve during several decades to the current often top-notch, collaborative and forward-looking state of today. I’m happy to serve as the EVBO president for some time. My mission will be to make European vascular biology research visible internationally, and in particular, promote a new generation of European vascular biologists.
5 selected recent publications
- Honkura N, Richards M, Laviña B, Sáinz-Jaspeado M, Betsholtz C, Claesson-Welsh L. Non-invasive imaging and novel image analysis of dynamic events in the vasculature. Nat Commun. 2018 Jul 16;9(1):2746
- Li X, Padhan N, Sjöström EO, Roche F, Testini C, Honkura N, Sainz-Jaspeado M, Gordon E, Bentley K, Philippides A, Tolmachev T, Dejana E, Stan, RV, Vestweber D, Ballmer-Hofer K, Betsholtz C, Pietras K, Jansson L, Claesson-Welsh L. VEGFR2 pY949 signaling regulates c-Src dynamics and VEGF-induced vascular permeability in cancer and metastatic spread. Nat Commun. 2016 Mar 23;7:11017
- Koch S, van Meeteren L, Morin E, Testini C, Weström S, Bjorkelund H, le Jan S, Berger P, Claesson-Welsh L. Neuropilin-1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev Cell 2014, E-pub March 18.
- Hayashi M, Majumdar A, Li X, Adler J, Sun Z, Vertuani S, Hellberg C, Mellberg S, Koch S, Dimberg A, Koh GY, Dejana E, Belting HG, Affolter M, Thurston G, Holmgren L, Vestweber D, Claesson-Welsh L. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat Commun. 2013;4:1672.
- HRG inhibits tunor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L*, Carmeliet P*. Cancer Cell. 2011 Jan 18;19(1):31-44. *) equal contribution